New drug aims to boost red blood cells after transplant

NCT ID NCT07636486

Not yet recruiting Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for blood transfusions and improves hemoglobin levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Luspatercept
What this could lead to: If it works, this could offer a more effective treatment for poor red blood cell recovery after stem cell transplant, reducing the need for transfusions.
What could go wrong: This is a Phase 2/3 trial with only 90 participants, so results may not apply broadly. Luspatercept may not work better than epoetin, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPOETIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPOETIN HEMATOLOGICAL MALIGNANCIES LUSPATERCEPT POOR ERYTHROID ENGRAFTMENT

Contacts and locations

Locations

Department of Hematology, Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.